Related Experiment Video
Updated: Nov 19, 2025
Author Spotlight: Advancements and Challenges in Machine Perfusion for Liver Transplantation
Published on: June 14, 2024
Physostigmine for prevention of postoperative delirium and long-term cognitive dysfunction in liver surgery: A
Claudia D Spies1, Cornelia Knaak, Mandy Mertens
1From the Department of Anaesthesiology and Intensive Care Medicine (CCM, CVK), Charité - Universitätsmedizin Berlin, and Berlin Institute of Health (CDS, CK, MM, W-RB, AS, AF, OM, VK, MF, WA, FB), Institute of Biometry and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, and Berlin Institute of Health (JW, KDW, SKP), Berlin Institute of Health (BIH), Anna-Louisa-Karsch 2, Berlin, Germany (JW, SKP), Addenbrooke's Hospital, Division of Anaesthesia, University of Cambridge, Cambridge, UK (KK, DKM), Department of Surgery (JP), Institute of Immunology, Charité - Universitätsmedizin Berlin, and Berlin Institute of Health (LA), Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Berlin, Germany (LA), Critical Illness, Brain Dysfunction, and Survivorship (CIBS) Center, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, and the Veteran's Affairs Tennessee Valley Geriatric Research Education Clinical Center (GRECC), USA (EWE) and SOSTANA GmbH Berlin, Germany (KDW).
Background:
Anecdotally, cholinergic stimulation has been used to treat delirium and reduce cognitive dysfunction.
Objective:
The aim of this investigation was to evaluate whether physostigmine reduced the incidence of postoperative delirium (POD) and postoperative cognitive dysfunction (POCD) in patients undergoing liver resection.
Design:
This was a double-blind, randomised, placebo-controlled trial. Between 11 August 2009 and 3 March 2016, patients were recruited at the Charité - Universitätsmedizin Berlin in Germany. Follow-ups took place at 1 week (T1), 90 days (T2) and 365 days (T3) after surgery.
Setting:
This single-centre study was conducted at an academic medical centre.
Participants:
In total, 261 participants aged at least 18 years scheduled for elective liver surgery were randomised. The protocol also included 45 non-surgical matched controls to provide normative data for POCD and neurocognitive deficit (NCD).
Intervention:
Participants were allocated to receive either intravenous physostigmine, as a bolus of 0.02 mg kg-1 body weight followed by 0.01 mg kg-1 body weight per hour (n = 130), or placebo (n = 131), for 24 h after induction of anaesthesia.
Main Outcomes And Measures:
Primary outcomes were POD, assessed using the Diagnostic and Statistical Manual of Mental Disorders (DSM-4-TR) twice daily up to day 7 after surgery, and POCD assessed via the CANTAB neuropsychological test battery, and two paper pencil tests on the day before surgery, and on postoperative days 7, 90 and 365.
Results:
In total, 261 patients were randomised, 130 to the physostigmine and 131 to the placebo group. The incidence of POD did not differ significantly between the physostigmine and placebo groups (20 versus 15%; P = 0.334). Preoperative cognitive impairment and POCD frequencies did not differ significantly between the physostigmine and placebo groups at any time. Lower mortality rates were found in the physostigmine group compared with placebo at 3 months [2% (95% confidence interval (CI), 0 to 4) versus 11% (95% CI, 6 to 16), P = 0.002], and 6 months [7% (95% CI, 3 to 12) versus 16% (95% CI, 10 to 23), P = 0.012] after surgery.
Conclusion:
Physostigmine had no effect on POD and POCD when applied after induction of anaesthesia up to 24 h.
Trial Registration:
DOI 10.1186/ISRCTN18978802, EudraCT 2008-007237-47, Ethics approval ZS EK 11 618/08 (15 January 2009).
Related Concept Videos
01:19Depolarizing Blockers: Pharmocokinetics
01:26Endoscopic Procedures IV: Sigmoidoscopy and Laproscopy
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
01:22Alzheimer's Disease: Treatment
01:31Skeletal Muscle Relaxants: Therapeutic Uses
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics